We are well aware of the multifactorial nature of hypertension, as well as the fact that it responds well to medication and lifestyle changes. It can be treated with renal denervation (RDN), which has been shown safe and effective in several randomized and non-randomized studies. However, the group of patients that will benefit most from...
Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. María Sanalí Paiva, entitled “Tips and Tricks with Renal Denervation”
The Netrod System study included 205 patients with uncontrolled essential hypertension while taking two drugs (nifedipine and hydrochlorothiazide), who were randomized 2:1 to denervation or sham control. All subjects had undergone renal angiography before randomization. Renal denervation was done using the Setrod System device. Mean patient age was 50 years old, and 16% of subjects were female....
This study included 219 patients with uncontrolled essential hypertension who had received at least two antihypertensive drugs. All of them underwent a renal angiography and were randomized to the renal denervation group or the control group. Denervation was performed using the SyMapCath I catheter and the SYMPIONEER S1 generator/stimulator. Mean patient age was 45 years old, and...
Most hypertensive patients do not reach target blood pressure level ranges despite optimal medical treatment. Regardless anti-hypertensive medication, patients undergoing radiofrequency renal denervation have seen significant improved control of blood pressure, with relevant clinical impact. One of the outcomes we look at in chronic diseases such as hypertension and diabetes is time in target range...
Thirty-eight patients were enrolled in the renal denervation (RDN) group, and 42 in the control group. The mean ambulatory systolic blood pressure and the mean ambulatory diastolic blood pressure were significantly lower at 24 and 36 months for patients in the RDN group compared with the control group, despite similar medical treatment with antihypertensive drugs....
Endovascular ultrasound renal denervation significantly reduces systolic blood pressure when compared against a sham procedure according to this new study presented at ACC 2021 simultaneously published in the Lancet. Renal denervation reduces ambulatory daily systolic blood pressure by 8 mmHg vs 3 mmHg in the sham procedure branch. This translates into a mean 4.5 mmHg...
Additional analyses from the Global SYMPLICITY Registry and the RADIANCE-HTN SOLO trial, presented virtually at EuroPCR 2020, can contribute to the comeback of renal denervation as another alternative for patients with uncontrolled hypertension. The 3-year results from the SYMPLICITY registry showed significant and durable reductions in blood pressure regardless of how many medications patients were taking....
In patients with uncontrolled hypertension who do not comply with treatment, renal denervation can generate benefit by reducing both ambulatory and office blood pressure, compared with patients who underwent a sham procedure. This new information emerges from the SPYRAL HTN-OFF MED trial, presented virtually at the American College of Cardiology (ACC) 2020 Scientific Session and...